Evidence map›Paper›PMID 30893581›Full record

ArticleImmunity2019

Sugar Fix Keeps RIPK3 at Bay.

Cristina Giogha, Kate E Lawlor

Abstract readComment
PubMed Publisher
In one paragraph

Article in Immunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Cristina GioghaCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia. Electronic address: cristina.giogha@hudson.org.au.
Kate E LawlorCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia; Department of Molecular and Translational Science, Monash University, Clayton, VIC 3168, Australia. Electronic address: kate.lawlor@hudson.org.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunometabolism is emerging as an important modulator of immune responses. In this issue of Immunity, Li et al. (2019) examine the link between lipopolysaccharide (LPS)-induced glucose metabolism and innate immune signaling and identify how β-N-acetylglucosamine (O-GlcNAc) modification of the RIPK3 RHIM domain limits inflammation and necroptosis.

Indexed as

InflammationSugarsHumansN-AcetylglucosaminyltransferasesReceptor-Interacting Protein Serine-Threonine KinasesSerineThreonineN-AcetylglucosaminyltransferasesO-GlcNAc transferaseReceptor-Interacting Protein Serine-Threonine KinasesRIPK3 protein, humanSerineSugarsThreonine

Identifiers

PMID30893581

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.